Diagnostic, Therapeutic and Prognostic Implications of Urothelial Carcinoma, A Review: Implications of Urothelial Carcinoma

Muhammad  Shahzad; Muhammad  Nasir Jamil; Hamza  Ashraf; Ehsan  Ul Islam

doi:10.54393/pjhs.v4i05.720

Authors

Muhammad Shahzad Ayub Medical Teaching Hospital, Abbottabad, Pakistan
Muhammad Nasir Jamil Ayub Medical Teaching Hospital, Abbottabad, Pakistan
Hamza Ashraf Women Medical College, Abbottabad, Pakistan
Ehsan Ul Islam Ayub Medical Teaching Hospital, Abbottabad, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v4i05.720

Keywords:

Urothelial Carcinoma, Bladder Cancer, Therapeutic, Diagnostic, Implications

Abstract

Urothelial carcinomas are cancerous tumors that can affect both the lower and upper urinary system and develop from the urothelial epithelium. The majority of urinary tract cancers (90–95%) are bladder tumors. UTUCs are rare, making up just 5–10% of UCs and their annual prevalence in Western nations is thought to be close to two instances per 100,000 people. This review of the article gives a general overview of the introduction, classification, diagnostic and therapeutic importance of urothelial carcinoma. About 48 recent publications, suitable for literature review, were retrieved from three different databases: PubMed, Sci. hub, and Google scholar. Careful reading and analysis of the literature review was carried out using inclusion and exclusion criteria. Despite significant improvements in prognosis and treatment, such as surgical methods, different adjuvant therapies, radical cystectomy, and robot-assisted radical cystectomy, tumors still recur with a dismal 5-year survival rate, making the addition of novel target-based therapies necessary to improve the overall outcome. Future treatments targeting genomic changes and the immune system should be tailored to each person's molecular profile. The majority of cases of urothelial carcinoma have been linked to numerous risk factors. For individuals with metastatic urothelial cancer, which includes bladder cancer and cancers of the upper urinary tract and urethra, numerous therapy options have been made available recently. These include targeted therapies and immunotherapy. This review recommended the possible way for diagnostic, therapeutic and prognostic implications of urothelial carcinoma.

References

Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, C, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. European Urology. 2021 Jan; 79(1): 62-79. doi: 10.1016/j.eururo.2020.05.042.

Miyazaki J and Nishiyama H. Epidemiology of urothelial carcinoma. International Journal of Urology. 2017 Oct; 24(10): 730-4. doi: 10.1111/iju.13376.

Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. European Urology. 2018 Jan; 73(1): 111-22. doi: 10.1016/j.eururo.2017.07.036.

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Medical Sciences. 2020 Mar; 8(1): 15. doi: 10.3390/medsci8010015.

Saad FT, Hincal E, Kaymakamzade B. Dynamics of immune checkpoints, immune system, and BCG in the treatment of superficial bladder cancer. Computational and Mathematical Methods in Medicine. 2017 Oct; 2017: 3573082. doi: 10.1155/2017/3573082.

Crabb SJ and Douglas J. The latest treatment options for bladder cancer. British Medical Bulletin. 2018 Dec; 128: 85-95. doi: 10.1093/bmb/ldy034.

Silva AL, Abreu-Mendes P, Martins D, Mendes F. The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder Cancer. Oncology. 2021 Mar; 1(1): 3-22. doi: 10.3390/onco1010002.

Annels NE, Simpson GR, Pandha H. Modifying the non-muscle invasive bladder cancer immune microenvironment for optimal therapeutic response. Frontiers in Oncology. 2020 Feb; 10: 175. doi: 10.3389/fonc.2020.00175.

Zichi C, Tucci M, Leone G, Buttigliero C, Vignani F, Pignataro D, et al. Immunotherapy for patients with advanced urothelial cancer: current evidence and future perspectives. BioMed Research International. 2017 Jun; 2017: 5618174. doi: 10.1155/2017/5618174.

Powles T, Walker J, Williams JA, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews. 2020 Jan; 82: 101925. doi: 10.1016/j.ctrv.2019.101925.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. European Urology. 2017 Jan; 71(1): 96-108. doi: 10.1016/j.eururo.2016.06.010.

Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU International. 2005 Jan; 95(1): 59-63. doi: 10.1111/j.1464-410X.2005.05249.x.

Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. Journal of the National Cancer Institute. 2011 Jan; 103(2): 117-28. doi: 10.1093/jnci/djq495.

Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. European Urology. 2014 Aug; 66(2): 253-62. doi: 10.1016/j.eururo.2014.01.006.

Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Japanese Journal of Clinical Oncology. 2015 Sep; 45(9): 884-91. doi: 10.1093/jjco/hyv088.

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. European Urology. 2013 Feb; 63(2): 234-41. doi: 10.1016/j.eururo.2012.07.033.

Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. European Urology. 2016 Sep; 70(3): 458-66. doi: 10.1016/j.eururo.2015.06.042.

Cumberbatch MG, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. European Urology. 2018 Dec; 74(6): 784-95. doi: 10.1016/j.eururo.2018.09.001.

Pietzak EJ, Mucksavage P, Guzzo TJ, Malkowicz SB. Heavy cigarette smoking and aggressive bladder cancer at initial presentation. Urology. 2015 Nov; 86(5): 968-73. doi: 10.1016/j.urology.2015.05.040.

Chang SS. Re: Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. The Journal of Urology. 2015 May; 193(5): 1517-8. doi: 10.1016/j.juro.2015.02.028.

Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015 Mar; 58: 493-504. doi: 10.1007/s00125-014-3456-9.

Rota M, Bosetti C, Boccia S, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to 2014. Archives of Toxicology. 2014 Aug; 88: 1479-90. doi: 10.1007/s00204-014-1296-5.

Montazeri K and Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020 Jan; 13(1): 1-6. doi: 10.1080/17512433.2020.1702025.

Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. European Urology. 2014 Jul; 66(1): 59-73. doi: 10.1016/j.eururo.2013.10.001.

Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, et al. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. Nature Communications. 2017 Jul; 8(1): 103. doi: 10.1038/s41467-017-00147-w.

Galsky MD, Saci A, Szabo P, Wang L, Zhu J, Azrilevich A, et al. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).Journal of Clinical Oncology. 2018 Jan; 36(6): 511-511. doi: 10.1200/JCO.2018.36.6_suppl.511.

Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. The Scientific World Journal. 2018 Oct; 2018: 5682078. doi: 10.1155/2018/5682078.

Nadal R and Bellmunt J. Management of metastatic bladder cancer. Cancer Treatment Reviews. 2019 Jun; 76: 10-21. doi: 10.1016/j.ctrv.2019.04.002.

Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. European Urology. 2014 Apr; 65(4): 778-92. doi: 10.1016/j.eururo.2013.11.046.

Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER. Effect of immunotherapy on local treatment of genitourinary malignancies. European Urology Oncology. 2019 Jul; 2(4): 355-64. doi: 10.1016/j.euo.2019.01.002.

Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, et al. Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. JNCI: Journal of the National Cancer Institute. 2021 Jan; 113(1): 48-53. doi: 10.1093/jnci/djaa076.

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Luciano R, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. European Urology. 2020 Apr; 77(4): 439-46. doi: 10.1016/j.eururo.2019.10.026.

Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clinical Cancer Research. 2022 Dec; 28(23): 5107-14. doi: 10.1158/1078-0432.CCR-22-2158.

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine. 2019 Nov; 25(11): 1706-14. doi: 10.1038/s41591-019-0628-7.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, et al. Role of checkpoint inhibition in localized bladder cancer. European Urology Oncology. 2018 Aug; 1(3): 190-8. doi: 10.1016/j.euo.2018.05.002.

Leow JJ, Liu Z, Tan TW, Lee YM, Yeo EK, Chong YL. Optimal management of upper tract urothelial carcinoma: current perspectives. OncoTargets and Therapy. 2020 Jan; 13: 1. doi: 10.2147/OTT.S225301.

Ulbright TM, Amin MB, Balzer B, Berney DM, Epstein JI, Guo C, et al. WHO Classification of Tumors of the Urinary System and Male Genital Organs. In Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors, WHO Classification of Tumors of the Urinary System and Male Genital Organs. 2016; 4(8): 189-226.

Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of urothelial carcinoma and the new “World Health Organisation classification of tumors of the urinary system and male genital organs 2016”. European Urology Focus. 2019 May; 5(3): 457-66. doi: 10.1016/j.euf.2018.01.003.

Kokorovic A and Matin SF. UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma. Therapeutic Advances in Medical Oncology. 2020 Jul; 12: 1758835920937950. doi: 10.1177/1758835920937950.

Magers MJ, Lopez‐Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology. 2019 Jan; 74(1): 112-34. doi: 10.1111/his.13734.

Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology. 2017 Mar; 35: 379-87. doi: 10.1007/s00345-016-1928-x.

Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World Journal of Urology. 2020 May; 38: 1165-75. doi: 10.1007/s00345-019-02875-8.

Territo A, Gallioli A, Meneghetti I, Fontana M, Huguet J, Palou J, et al. Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe? Arab Journal of Urology. 2021 Jan; 19(1): 46-58. doi: 10.1080/2090598X.2021.1883810.

Keller EX, Doizi S, Villa L, Traxer O. Which flexible ureteroscope is the best for upper tract urothelial carcinoma treatment?. World Journal of Urology. 2019 Nov; 37: 2325-33. doi: 10.1007/s00345-019-02675-0.

Hasan MN, Rouprêt M, Keeley F, Cracco C, Jones R, Straub M, et al.Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology. 2019 Nov; 37: 2289-96. doi: 10.1007/s00345-019-02739-1.

Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World Journal of Urology. 2017 Mar; 35: 337-53. doi: 10.1007/s00345-016-1826-2.

Wang Q, Zhang T, Wu J, Wen J, Tao D, Wan T, et al. Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China. BMC Urology. 2019 Dec; 19(1): 1-8. doi: 10.1186/s12894-019-0457-5.

Carrion A, Huguet J, García-Cruz E, Izquierdo L, Mateu L, Musquera M, et al. Intraoperative prognostic factors and atypical patterns of recurrence in patients with upper urinary tract urothelial carcinoma treated with laparoscopic radical nephroureterectomy. Scandinavian Journal of Urology. 2016 Jul; 50(4): 305-12. doi: 10.3109/21681805.2016.1144219.